You searched for "EU"
EU: is it time to leave and embrace the world?
1 June 2016
| Rod McNeil
|
EYE - General
Should the United Kingdom remain a member of the European Union (EU) or leave? It’s a big decision involving some complex issues, and there’s no doubt the EU will continue to change. Ipsos MORI’s monthly EU voting intention poll published...
Regulatory drug evaluations and expedited review initiatives: EU and US perspectives
1 April 2016
| Rod McNeil
|
EYE - General
The European Medicines Agency (EMA) and United States Food and Drug Administration (FDA) each conduct independent assessments of benefit-risk profile when evaluating applications to market new or modified medicines, and their respective decision-making is guided by distinct legislation, procedures and...
Post-Brexit deal welcomed but leaves future relationship with EU far from settled
6 April 2021
| Rod McNeil
|
EYE - General
Rod McNeil breaks down the impact of the Brexit deal on healthcare in the UK, including medicines regulation, research funding, sharing of information and the ability to work abroad. A disorderly no-deal exit from the European Union (EU) was averted...
Booster accelerates EU-funded projects results to create tangible impact
META Group is proud to announce that Booster has been renewed for another four years, with additional and customised services. Funded by the European Commission’s Directorate-General for Research and Innovation (DG RTD) and led by META Group, Booster offers a...Brexit, for richer, for poorer: prospects for post-withdrawal Britain
1 July 2017
| Rod McNeil
|
EYE - General
The people of the United Kingdom voted by 52% to 48% to leave the European Union (EU) in June 2016, a referendum decision intended by a slim majority to restore national self-determination and achieve what many believed to be a...
Informed consent – the Brexit test
1 August 2016
| Gwyn Samuel Williams
|
EYE - Cataract, EYE - Cornea, EYE - Glaucoma, EYE - Imaging, EYE - Neuro-ophthalmology, EYE - Oculoplastic, EYE - Oncology, EYE - Orbit, EYE - Paediatrics, EYE - Pathology, EYE - Refractive, EYE - Strabismus, EYE - Vitreo-Retinal, EYE - General
The Medical Defence Union (MDU) runs courses on various medicolegal topics. I would guess people only ever attend these courses if they have an exam or an interview approaching as the subject matter is exceedingly dry for clinicians. I myself...
UK rejoins Horizon Europe research funding programme
19 September 2023
The UK government has announced that it will rejoin the €95bn Horizon Europe research framework.
Zeiss field machines, public Wi-Fi risks and IoT scanning
1 April 2017
| David Haider
|
EYE - Imaging
End of support for old field machines Zeiss have recently announced that they are withdrawing support contracts for many of their older 7 series Humphrey Field Analysers (HFAs) in November 2017. They have confirmed maintenance contracts can continue, but repairs...
Visual consequences of congenital hypothyroidism
1 December 2016
| Fiona Rowe (Prof)
|
Paediatric Ophthalmology / Strabismus
This study evaluated the frequencies of ophthalmic abnormalities in Turkish children with a history of congenital hypothyroidism in a retrospective study of 121 children. Median age was nine months (one to 216) at initial ophthalmic examination. Forty children were ex-premature...
Deadline approaching for Edinburgh scholarship applications
19 June 2019
The University of Edinburgh has opened applications for scholarships to its two online courses, the MSc in Primary Care Ophthalmology and the ChM in Clinical Ophthalmology.
OSA Sustainability Committee holds first meeting
4 August 2021
The OSA Sustainability Committee held its first meeting on Friday 23 July. The aim of the committee is to provide information, support and advice to OSA members who want to
demonstrate their commitment to behaving in a more environmentally sensitive and more sustainable way.
Rare eye diseases: progress continues with authorised orphan medicines and breakthrough technologies
1 October 2018
| Rod McNeil
|
EYE - General
An update on the development of orphan medicines, recent regulatory treatment approvals for rare eye conditions and advances in retinal prosthetic technologies for blinding diseases. The prevalence of a rare disease is based usually on a range of estimates and...
